Functional Recovery in Autoimmune Encephalitis: A Prospective Observational Study.

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Limited prospective data exists on functional recovery in autoimmune encephalitis (AE) patients with synaptic and neuronal cell surface receptor antibodies.
• Autoimmune encephalitis encompasses a spectrum of conditions with varying prognoses.

Purpose of the Study:

• To prospectively observe and compare functional recovery in adult AE patients based on their specific antibody status.
• To evaluate the utility of the modified Rankin Scale (mRS) in assessing recovery across different AE subtypes.

Main Methods:

• A prospective registry of adult AE patients was established.
• Functional recovery was assessed using the modified Rankin Scale (mRS) at 3, 6, and 12 months post-diagnosis.
• Patients were stratified into three groups based on antibody status: anti-NMDAR-Ab, anti-LGI1/CASPR2-Ab, and other antibodies.

Main Results:

• Patients with anti-NMDAR-Ab (Group I) and other antibodies (Group III) had significantly higher median mRS scores at 3 months compared to anti-LGI1/CASPR2-Ab (Group II) patients.
• A median mRS of 1 was consistently observed in Group II patients across all follow-up points, indicating better functional recovery.
• Group II patients had a higher incidence of seizures, while Group III patients frequently had underlying cancer and included those with anti-GABA_BR, anti-GAD65, and anti-GlyR antibodies.

Conclusions:

• Recovery dynamics differ significantly among AE subtypes, impacting clinical trial design.
• The high rate of disability at 3 months in anti-NMDAR-Ab and other AE groups necessitates improved treatment strategies.
• The modified Rankin Scale may be insufficient for differentiating subtle neurological improvements in anti-LGI1/CASPR2 encephalitis.